Chalmers Development Corp acquires PRIMUS

Chalmers Development Corporation has acquired Omaha, Nebraska-based PRIMUS Sterilizer Company, a maker of sterilizer equipment. No financial terms were disclosed. Livingstone was financial adviser to PRIMUS on the deal. PRIMUS was backed by Blue Sage Capital. Queen Saenz + Schutz PLLC provided legal counsel to both PRIMUS and Blue Sage Capital. Chalmers Development Corporation is a subsidiary of Ontario-based Chalmers Group of Companies.


CHICAGO, November 20, 2018 – Livingstone is pleased to announce the sale of PRIMUS Sterilizer Company, L.L.C. (“PRIMUS” or “the Company”), a portfolio company of Blue Sage Capital, to Chalmers Development Corporation, a subsidiary of Ontario-headquartered Chalmers Group of Companies (collectively, “Chalmers”). Livingstone acted as exclusive financial advisor to PRIMUS.

Omaha-based PRIMUS Sterilizer Company is the largest U.S.-based manufacturer of mission-critical steam sterilizers, and provider of related aftermarket services into laboratory, biopharmaceutical, clinical, and vivarium end markets.

The Company’s 19 standard autoclave sizes, along with its ability to create custom configurations, allows PRIMUS’s products to serve a wide range of research, development, testing, healthcare, and other similar applications. Accordingly, the Company has built strong relationships with an extensive list of distinguished customers, including: Centers for Disease Control and Prevention, Children’s Hospital of Philadelphia, Johns Hopkins University, Nationwide Children’s Hospital, Stanford University, U.S. Food & Drug Administration, University of California – Berkley, University of Chicago, University of Nebraska Medical Center, University of Washington, Yale University, and many of the largest biopharmaceutical companies in the U.S.

“Livingstone was instrumental in every facet of preparing our team for market and leading the PRIMUS team to a successful closing with Chalmers,” said Jim Fry, CEO of PRIMUS. “In recent years, PRIMUS and Chalmers have proven their strategic fit by successfully pursuing sterilizer and washer opportunities on a joint-venture basis. The official combination of these two world-class companies formalizes our already-tested go-to-market approach.”

PRIMUS joins a family of three other Chalmers’ subsidiaries, including Scientek Technology Corporation of Vancouver, British Columbia (“Scientek”), and CSI/Jewett of Erie, PA, to form the Chalmers Medical Group.

“We are excited to add PRIMUS to our portfolio of businesses and welcome Jim Fry and the entire PRIMUS team to our corporate family,” said Harinder Takhar, CEO of Chalmers Group of Companies. “We strongly believe that the synergies between Chalmers and PRIMUS will lead to stronger performance and growth opportunities for the combined company.”

“On behalf of our global industrial team, we are pleased to have worked with both Blue Sage and Jim and his team to drive our ninth successful lab products transaction as part of our Industrial Technology sector practice. It is our Global Industrial team’s 32nd closing in the last year,” said Andrew Isgrig, Partner at Livingstone.

“Chalmers is the perfect partner for PRIMUS. Together, they will leverage their complementary operational capabilities, product & service offerings, and sales forces to better serve their customers and grow market share,” added Robert Tymowski, Director at Livingstone.

Queen Saenz + Schutz PLLC provided legal counsel to both PRIMUS and Blue Sage Capital throughout the process.

Livingstone has more than 120 professionals across offices in Chicago, Los Angeles, Beijing, Düsseldorf, London, Madrid, and Stockholm. The firm has deep industry expertise, and extensive global coverage, with dedicated teams across all offices serving five segments: Business Services, Consumer, Healthcare, Industrial, and Media & Technology.